drugset / Trial / NCT03569280
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, multicenter study of KPG-121 administered orally once daily (QD) in 28-day treatment cycles to adult subjects.
Timeline
- Start
- 2019-11-26
- Primary completion
- 2023-01-10
- Completion
- 2023-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | — |
| Subject | Apalutamide | Small molecule | — | — |
| Subject | Enzalutamide | Other / unclassified | — | — |